Discover J&J
Medicines & therapies
Medical devices & technology
Discover J&J
Medicines & therapies
Medical devices & technology
Careers
Media
Contact
locationPlaceholder
Choose your country or region
Global
Global
English
North America
North America (Regional)
English
Canada
English
Français
United States
English
Asia Pacific
Asia Pacific (Regional)
English
Australia
English
China
中文
Hong Kong
English
中文
Japan
日本
Korea
한국어
New Zealand
English
Europe, Middle East & Africa (EMEA)
EMEA (Regional)
English
Middle East - Africa
الشرق الأوسط و أفريقيا (عربي)
Austria
Deutsch
Belgium
English
Français
Nederlands
Bulgaria
БЪЛГАРСКИ
Croatia
Hrvatski
Czech Republic
čeština
Denmark
Dansk
Estonia
English
Finland
Suomi
France
Français
Germany
Deutsch
Greece
ΕΛΛΗΝΙΚΑ
Hungary
Magyar
Ireland
English
Israel
עברית
Italy
Italiano
Latvia
English
Lithuania
English
Netherlands
Nederlands
Norway
Norsk
Poland
Polski
Portugal
Português
Romania
Română
Russia
Pусский
Serbia
Srpski
Slovakia
Slovenčina
Slovenia
Slovenščina
South Africa
English
Spain
Español
Switzerland
Français
Deutsch
Sweden
Svensk
Turkey
Türkçe
United Kingdom
English
Latin America
Latin America (Regional)
Español
Argentina
Español
Bolivia
Español
Brazil
Português
Central America and the Caribbean
Español
Chile
Español
Colombia
Español
Ecuador
Español
Mexico
Español
Paraguay
Español
Peru
Español
Uruguay
Español
Healthcare areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Products
Clinical trials
Pipeline
Patient resources
Innovative Medicine
healthcare areas
Menu
Healthcare areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Products
Clinical trials
Pipeline
Patient resources
Careers
Media
Contact
Show Search
Search Query
Clear
Submit Search
Dictate search request
Listening...
Search Results
No Results
See all results
Sorry, I don't understand. Please try again
Search Results
Search Query
Submit Search
Listening...
Dates
All (1123)
Last 7 days (2)
2024 (101)
2023 (75)
2022 (57)
2021 (67)
2020 (42)
2019 (68)
2018 (77)
2017 (80)
2016 (64)
Types
All (1123)
Article (56)
Page (7)
Press Release (1060)
There are 1,123 results that match your search.
Filters
Dates
All (1123)
Last 7 days (2)
2024 (101)
2023 (75)
2022 (57)
2021 (67)
2020 (42)
2019 (68)
2018 (77)
2017 (80)
2016 (64)
Types
All (1123)
Article (56)
Page (7)
Press Release (1060)
Relevance
Relevance
Newest
Oldest
Innovative Medicine
July 17, 2018
Janssen Announces U.S. FDA Approval of SYMTUZA™ (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
Read more
Innovative Medicine
July 16, 2018
Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA® (canagliflozin) is Being Stopped Early for Positive Efficacy Findings
Read more
Innovative Medicine
July 13, 2018
U.S. FDA Extends Review Timeline for INVOKANA® (canagliflozin) Supplemental New Drug Application
Read more
Innovative Medicine
July 11, 2018
Janssen Provides Update on IMBRUVICA® (ibrutinib) Phase 3 PHOENIX Trial in Newly Diagnosed Non-Germinal Center B Cell (Non-GCB) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL)
Read more
Innovative Medicine
July 6, 2018
Johnson & Johnson Announces Publication in The Lancet Highlighting Robust Immune Response to Janssen’s Mosaic-based Preventive Vaccine Regimen for HIV
Read more
Innovative Medicine
June 26, 2018
Champions of Science: The Art of Ending Stigma Project Launches to Combat Stigma About Mental Illnesses Through Education and Artistic Creation
Read more
Innovative Medicine
June 24, 2018
Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Read more
Innovative Medicine
June 23, 2018
Real-World Evidence Shows Oral INVOKANA® (canagliflozin) Results in Greater Weight Loss and Treatment Adherence Than Injectable GLP-1 Receptor Agonists in Type 2 Diabetes Patients
Read more
Innovative Medicine
June 19, 2018
Janssen Phase 3 Study Programme of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Presented for the First Time in Europe
Read more
Innovative Medicine
June 14, 2018
XARELTO® (rivaroxaban) Associated with Significantly Reduced Time in Hospital and Decreased Costs Compared to Standard of Care in New Study of Patients with Low-Risk Pulmonary Embolism (PE)
Read more
64 of 113
